Nuvalent Inc (NUVL)Healthcare | Biotechnology | Cambridge, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 10:49 a.m. UTC
The immediate catalyst driving this stock is the reported $10.6 billion acquisition bid from GSK, which explains the recent surge to record highs and the removal of Class A shares from Nasdaq. However, this event-driven rally masks a fundamentally broken business: the company is burning cash with negative free cash flow and operating cash flow, while posting significant losses on both assets and equity. The balance sheet shows a massive current ratio, but this reflects a capital structure likely inflated by the pending deal rather than organic operational strength. With no dividend history and a forward P/E that cannot be calculated due to negative earnings, there is no safety margin for a long-term hold outside of the acquisition premium. The statistical models offer no guidance due to insufficient data, confirming that the current price action is purely speculative event noise. Investors should view this as a binary outcome play on the deal closing, not a traditional investment thesis. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 9,792,580,608 |
| Forward P/E | -30.85 |
| Beta | 1.14 |
| Website | https://nuvalent.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5128143 |
| Address1 | One Broadway |
| Address2 | 14th Floor |
| All Time High | 123.99 |
| All Time Low | 7.09 |
| Ask | 123.97 |
| Ask Size | 500 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 1,050,498 |
| Average Volume | 2,329,979 |
| Average Volume10Days | 1,050,498 |
| Beta | 1.138 |
| Bid | 123.95 |
| Bid Size | 500 |
| Board Risk | 4 |
| Book Value | 14.888 |
| City | Cambridge |
| Compensation Risk | 7 |
| Country | United States |
| Currency | USD |
| Current Price | 123.96 |
| Current Ratio | 16.137 |
| Date Short Interest | 1,782,777,600 |
| Day High | 123.9 |
| Day Low | 123.85 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 8,505,105,408 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 114.664 |
| Fifty Two Week High | 123.99 |
| Fifty Two Week Low | 71.13 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,122,200 |
| Float Shares | 49,108,264 |
| Forward Eps | -4.22483 |
| Forward P E | -30.852169 |
| Free Cashflow | -180,427,744 |
| Full Time Employees | 234 |
| Fullday Change | 123.96 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 123.96 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Held Percent Insiders | 0.02781 |
| Held Percent Institutions | 1.13302 |
| Implied Shares Outstanding | 78,997,915 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc. to develop companion diagnostics therapies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Nuvalent Inc |
| Market Cap | 9,792,580,608 |
| Max Age | 86,400 |
| Message Board Id | finmb_702442629 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -450,073,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Number Of Analyst Opinions | 9 |
| Open | 123.87 |
| Operating Cashflow | -312,787,008 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 857 357 7000 |
| Previous Close | 0.0 |
| Price Hint | 2 |
| Price To Book | 8.326169 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.885 |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 3.0 |
| Regular Market Day High | 123.9 |
| Regular Market Day Low | 123.85 |
| Regular Market Open | 123.87 |
| Regular Market Previous Close | 0.0 |
| Regular Market Volume | 1,489,608 |
| Return On Assets | -0.22513 |
| Return On Equity | -0.41189 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 73,562,661 |
| Shares Percent Shares Out | 0.0368 |
| Shares Short | 2,908,403 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 5,241,004 |
| Short Name | Nuvalent, Inc. |
| Short Percent Of Float | 0.0617 |
| Short Ratio | 0.56 |
| State | MA |
| Symbol | NUVL |
| Target High Price | 124.0 |
| Target Low Price | 124.0 |
| Target Mean Price | 124.0 |
| Target Median Price | 124.0 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 1,287,475,968 |
| Total Cash Per Share | 16.298 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | NaN |
| Trailing Eps | -6.06 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 105.258026 |
| Underlying Symbol | NUVL |
| Uuid | 6d3cb61d-60b2-3511-a49b-f3aa9d7c84d1 |
| Volume | 1,489,608 |
| Website | https://nuvalent.com |
| Zip | 2,142 |